Pioglitazone inhibits the development of hyperalgesia and sensitization of spinal nociresponsive neurons in type 2 diabetes

Thiazolidinedione drugs (TZDs) such as pioglitazone are FDA-approved for the treatment of insulin resistance in type 2 diabetes. However, whether TZDs reduce painful diabetic neuropathy (PDN) remains unknown. Therefore we tested the hypothesis that chronic administration of pioglitazone would reduce...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Pain
Main Authors: Griggs, Ryan B., Donahue, Renee R., Adkins, Braxton G., Anderson, Katie L., Thibault, Olivier, Taylor, Bradley K.
Formato: Artigo
Idioma:Inglês
Publicado: 2015
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791042/
https://ncbi.nlm.nih.gov/pubmed/26687453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jpain.2015.11.006
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares